|
1
|
Valery PC, Laversanne M and Bray F: Bone
cancer incidence by morphological subtype: A global assessment.
Cancer Causes Control. 26:1127–1139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saraf AJ, Fenger JM and Roberts RD:
Osteosarcoma: Accelerating progress makes for a hopeful future.
Front Oncol. 8:42018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fizazi K, Yang J, Peleg S, Sikes CR,
Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis
CJ, et al: Prostate cancer cells-osteoblast interaction shifts
expression of growth/survival-related genes in prostate cancer and
reduces expression of osteoprotegerin in osteoblasts. Clin Cancer
Res. 9:2587–2597. 2003.PubMed/NCBI
|
|
5
|
Otoukesh B, Boddouhi B, Moghtadaei M,
Kaghazian P and Kaghazian M: Novel molecular insights and new
therapeutic strategies in osteosarcoma. Cancer Cell Int.
18:1582018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bishop MW, Janeway KA and Gorlick R:
Future directions in the treatment of osteosarcoma. Curr Opin
Pediatr. 28:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nemeth K, Bayraktar R, Ferracin M and
Calin GA: Non-coding RNAs in disease: From mechanisms to
therapeutics. Nat Rev Genet. 25:211–232. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang K, Jiang W, Cheng C, Li Y and Tu M:
Pathological and therapeutic aspects of long noncoding RNAs in
osteosarcoma. Anticancer Agents Med Chem.
13:10.2174/1871520617666170213122442. 2017.
|
|
9
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang
S and Liu X: Long noncoding RNA MALAT1 as a potential therapeutic
target in osteosarcoma. J Orthop Res. 34:932–941. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu CX, Li X, Nan F, Jiang S, Gao X, Guo
SK, Xue W, Cui Y, Dong K, Ding H, et al: Structure and degradation
of circular RNAs regulate PKR activation in innate immunity. Cell.
177:865–880.e21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Memczak S, Jens M, Elefsinioti A, Torti F,
Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer
M, et al: Circular RNAs are a large class of animal RNAs with
regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Das A, Sinha T, Shyamal S and Panda AC:
Emerging role of circular RNA-protein interactions. Noncoding RNA.
7:482021.PubMed/NCBI
|
|
14
|
Wilusz JE and Sharp PA: Molecular biology.
A circuitous route to noncoding RNA. Science. 340:440–441. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang F, Chen Y, Xue Z, Lv Y, Shen L, Li K,
Zheng P, Pan P, Feng T, Jin L and Yao Y: High-throughput sequencing
and exploration of the lncRNA-circRNA-miRNA-mRNA network in type 2
diabetes mellitus. Biomed Res Int. 2020:81625242020.PubMed/NCBI
|
|
16
|
Trang NTN, Lai CY, Tsai HC, Huang YL, Liu
SC, Tsai CH, Fong YC, Tzeng HE and Tang CH: Apelin promotes
osteosarcoma metastasis by upregulating PLOD2 expression via the
Hippo signaling pathway and hsa_circ_0000004/miR-1303 axis. Int J
Biol Sci. 19:412–425. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu L, Zhu H, Wang Z, Huang J, Zhu Y, Fan
G, Wang Y, Chen X and Zhou G: Circular RNA circFIRRE drives
osteosarcoma progression and metastasis through
tumorigenic-angiogenic coupling. Mol Cancer. 21:1672022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang M, Yu GY, Liu G and Liu WD: Circular
RNA circ_0002137 regulated the progression of osteosarcoma through
regulating miR-433-3p/IGF1R axis. J Cell Mol Med. 26:1806–1816.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Qiu G, Luo Y, Li S, Xu Y, Zhang Y,
Hu J, Li P, Pan H and Wang Y: Circular RNA ROCK1, a novel circRNA,
suppresses osteosarcoma proliferation and migration via altering
the miR-532-5p/PTEN axis. Exp Mol Med. 54:1024–1037. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rehmsmeier M, Steffen P, Höchsmann M and
Giegerich R: Fast and effective prediction of microRNA/target
duplexes. RNA. 10:1507–1517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riffo-Campos ÁL, Riquelme I and
Brebi-Mieville P: Tools for sequence-based miRNA target prediction:
What to choose? Int J Mol Sci. 17:19872016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk-database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vejnar CE, Blum M and Zdobnov EM: miRmap
web: Comprehensive microRNA target prediction online. Nucleic Acids
Res. 41:W165–W168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC,
Hsu PW, Wong YH, Chen YH, Chen GH and Huang HD: miRNAMap 2.0:
Genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res.
36:D165–D169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Goswami CP and Nakshatri H: PROGgeneV2:
Enhancements on the existing database. BMC Cancer. 14:9702014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gillespie EF, Yang JC, Mathis NJ, Marine
CB, White C, Zhang Z, Barker CA, Kotecha R, McIntosh A, Vaynrub M,
et al: Prophylactic radiation therapy versus standard of care for
patients with high-risk asymptomatic bone metastases: A
multicenter, randomized phase II clinical trial. J Clin Oncol.
42:38–46. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang J and Wang N: Analysis of the
molecular mechanism of osteosarcoma using a bioinformatics
approach. Oncol Lett. 12:3075–3080. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Liu S, Shi J, Li J, Wang S, Liu H,
Zhao S, Duan K, Pan X and Yi Z: The role of miRNA in the diagnosis,
prognosis, and treatment of osteosarcoma. Cancer Biother
Radiopharm. 34:605–613. 2019.PubMed/NCBI
|
|
31
|
Wang JY, Yang Y, Ma Y, Wang F, Xue A, Zhu
J, Yang H, Chen Q, Chen M, Ye L, et al: Potential regulatory role
of lncRNA-miRNA-mRNA axis in osteosarcoma. Biomed Pharmacother.
121:1096272020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hei R, Chen J, Zhang X, Bian H, Chen C, Wu
X, Han T, Zhang Y, Gu J, Lu Y and Zheng Q: CircNRIP1 acts as a
sponge of miR-1200 to suppress osteosarcoma progression via
upregulation of MIA2. Am J Cancer Res. 12:2833–2849.
2022.PubMed/NCBI
|
|
33
|
Qin S, Wang Y, Ma C and Lv Q: Competitive
endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma
chemoresistance. Eur J Med Res. 28:3542023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui H and Zhao J: LncRNA TMPO-AS1 serves
as a ceRNA to promote osteosarcoma tumorigenesis by regulating
miR-199a-5p/WNT7B axis. J Cell Biochem. 121:2284–2293. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun Y, Cao L, Lin JT, Yuan Y, Cao ZL and
Jia JD: Upregulated miRNA-1236-3p in osteosarcoma inhibits cell
proliferation and induces apoptosis via targeting KLF8. Eur Rev Med
Pharmacol Sci. 23:6053–6061. 2019.PubMed/NCBI
|
|
36
|
Jeck WR, Sorrentino JA, Wang K, Slevin MK,
Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are
abundant, conserved, and associated with ALU repeats. RNA.
19:141–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li R, Jiang J, Shi H, Qian H, Zhang X and
Xu W: CircRNA: A rising star in gastric cancer. Cell Mol Life Sci.
77:1661–1680. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ju HQ, Zhao Q, Wang F, Lan P, Wang Z, Zuo
ZX, Wu QN, Fan XJ, Mo HY, Chen L, et al: A circRNA signature
predicts postoperative recurrence in stage II/III colon cancer.
EMBO Mol Med. 11:e101682019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zong L, Sun Q, Zhang H, Chen Z, Deng Y, Li
D and Zhang L: Increased expression of circRNA_102231 in lung
cancer and its clinical significance. Biomed Pharmacother.
102:639–644. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song T, Xu A, Zhang Z, Gao F, Zhao L, Chen
X, Gao J and Kong X: CircRNA hsa_circRNA_101996 increases cervical
cancer proliferation and invasion through activating TPX2
expression by restraining miR-8075. J Cell Physiol.
234:14296–14305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y,
Huang K, Wang G, Wang J, Ma J, et al: Circular RNA circTADA2A
promotes osteosarcoma progression and metastasis by sponging
miR-203a-3p and regulating CREB3 expression. Mol Cancer. 18:732019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tang Q, Chen Z, Zhao L and Xu H: Circular
RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical
cancer progression through up-regulation of ELK1. Aging (Albany
NY). 11:9982–9999. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moya L, Meijer J, Schubert S, Matin F and
Batra J: Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289
expression as biomarker for prostate cancer diagnosis. Int J Mol
Sci. 20:11542019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wei L, Sun C, Zhang Y, Han N and Sun S:
miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and
lymphangiogenesis by directly downregulating VEGF-A. Gene Ther.
29:28–40. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jiang SP and Li ZR: MiR-503-5p regulates
cell epithelial-to-mesenchymal transition, metastasis and prognosis
of hepatocellular carcinoma through inhibiting WEE1. Eur Rev Med
Pharmacol Sci. 23:2028–2037. 2019.PubMed/NCBI
|
|
46
|
Liang X, Li Z, Men Q, Li Y, Li H and Chong
T: miR-326 functions as a tumor suppressor in human prostatic
carcinoma by targeting Mucin1. Biomed Pharmacother. 108:574–583.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Contino G, Amati F, Pucci S, Pontieri E,
Pichiorri F, Novelli A, Botta A, Mango R, Nardone AM, Sangiuolo FC,
et al: Expression analysis of the gene encoding for the U-box-type
ubiquitin ligase UBE4A in human tissues. Gene. 328:69–74. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sakiyama T, Fujita H and Tsubouchi H:
Autoantibodies against ubiquitination factor E4A (UBE4A) are
associated with severity of Crohn's disease. Inflamm Bowel Dis.
14:310–317. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yi X, Xiao F, Zhong X, Duan Y, Liu K and
Zhong C: A Ca2+ chelator ameliorates chromium (VI)-induced
hepatocyte L-02 injury via down-regulation of voltage-Dependent
anion channel 1 (VDAC1) expression. Environ Toxicol Pharmacol.
49:27–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu C, Li H, Duan W, Duan Y, Yu Q, Zhang
T, Sun YP, Li YY, Liu YS and Xu SC: MCU upregulation overactivates
mitophagy by promoting VDAC1 dimerization and ubiquitination in the
hepatotoxicity of cadmium. Adv Sci (Weinh). 10:22038692023.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shoshan-Barmatz V, De Pinto V,
Zweckstetter M, Raviv Z, Keinan N and Arbel N: VDAC, a
multi-functional mitochondrial protein regulating cell life and
death. Mol Aspects Med. 31:227–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shoshan-Barmatz V, Nahon-Crystal E,
Shteinfer-Kuzmine A and Gupta R: VDAC1, mitochondrial dysfunction,
and Alzheimer's disease. Pharmacol Res. 131:87–101. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang C, Ding W, Liu Y, Hu Z, Zhu D, Wang
X, Yu L, Wang L, Shen H, Zhang W, et al: Proteomics-based
identification of VDAC1 as a tumor promoter in cervical carcinoma.
Oncotarget. 7:52317–52328. 2016. View Article : Google Scholar : PubMed/NCBI
|
